GWB-PSFA8A

SRE Reporter - HEK293 Cell Line (ERK Pathway)

Ask for quotation

78327

SRE eGPF Reporter - HEK293 Cell Line (ERK Pathway)

Recombinant HEK-293 cells expressing enhanced green fluorescent protein (eGFP) under the control of SRE responsive elements. This cell line is validated for its response to EGF or serum stimulation and to treatment with inhibitors of ERK signaling pathway.

3598.13 €

79298

NFAT Reporter - Hek293 Cell Line (PKC/ Ca2+ Pathway)

The NFAT Reporter - Hek293 cell line contains a firefly luciferase gene under the control of NFAT response element stably integrated into Hek293 cells. This cell line is validated for the response to the stimulation of phorbol 12-myristate 13-acetate (PMA) with ionomycin.

3393.60 €

79798

TrkA / SRE Reporter - HEK293 Recombinant Cell Line

Recombinant HEK-293 cells expressing firefly luciferase gene under the control of Serum Response Elements (SRE) with constitutive expression of human TrkA (Tropomyosin receptor kinase A; NTRK1; ref. seq. NM_002529.3).

14392.50 €

79800-P

STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin)

The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

5802.45 €

60650

NF-κB reporter (Luc) - HEK293 Cell line

The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17.

2219.47 €